Greenwich Village Dermatology, New York, New York, 10012, United States - 01 Aug `26An Observational Study of Patients With Dermatologic Disease

An Observational Study of Patients With Dermatologic Disease

Official title: An Observational Study of Patients With Dermatologic Disease

Status: Opening soon

Description:

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Who can take part: 2000000 participants planned.

Enrollment status: Opening soon. The study started 01 September 2026 and is expected to finish 03 August 2041.

Contact: Lynda Lee Burch.

Source: ClinicalTrials.gov, NCT07748169 (https://clinicaltrials.gov/study/NCT07748169).

Start date: September 01, 2026

Completion date: August 03, 2041

Organizer: Target PharmaSolutions, Inc.

Contact: Lynda Lee Burch

Tel.: 9842340268

Email: lburch@pedestalhealth.com

Link: https://clinicaltrials.gov/study/NCT07748169

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference An Observational Study of Patients With Dermatologic Disease . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • What tests for vitiligo should be done?

    Before starting vitiligo therapy, several tests may be recommended to ensure an accurate diagnosis and appropriate treatment plan: Physical Examination A thorough physical exami...

  • Vitiligo trials for kids: basics for the parents

    Pediatric vitiligo trials · The basics Two parallel studies are evaluating investigational use of ruxolitinib cream in young children — researchers are still finding out how wel...

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...